

# Cost of Hepatitis C Drugs Anger Patients; CBCD Reviews a Report

*The drug's high cost is the source of a growing debate among healthcare professionals, drug makers, and patients.* (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, July 20, 2015 /EINPresswire.com/ --

“Infected with the hepatitis C virus (HCV)? The CBCD recommends taking [Novirin](#) or [Gene-Eden-VIR](#).” - Greg Bennett, CBCD

New hepatitis C (HCV) drugs are too expensive for most patients. For example, “a standard course of Sovaldi costs \$84,000, or \$1,000 a day. And many insurers would not approve it for any but the sickest of patients.” (1) Additionally, barriers have been put up by private insurance companies and state Medicaid programs “aimed at controlling costs (which have) made it hard for patients to get the drug, with many left to worsen as they sought charity or appealed their cases.” (1) Dr. Paul J. Thuluvath said “Here we had this disease we couldn't cure, and this drug is developed and it's almost like a miracle. I was so upset it was so expensive.” (1) Dr. Thuluvath is a professor at the University of Maryland School of Medicine and author of a forthcoming hepatitis guide.

An article in Forbes magazine noted that these high costs “are hitting Medicaid health insurance programs for poor Americans particularly hard because the population of patients in need of Hepatitis C treatments tends to have low incomes and wouldn't be able to afford the drug otherwise. Medicaid is funded by state and federal tax dollars and administered by state governments.” (2)



“For those infected with the latent HCV, we recommend Novirin or Gene-Eden-VIR. The formula of these natural HCV remedies was shown to reduce hepatitis C symptoms in two

guidelines.” – Greg Bennett, CBCD

Click to learn more about [HCV symptoms](#).

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against the hepatitis C virus, and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with HCV ... reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (3) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (3)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

It is interesting to note that “According to the Express Scripts Drug Trend Report, “specialty” drugs for chronic and difficult conditions accounted for just 1 percent of U.S. prescriptions but 31.8 percent of drug spending in 2014.” (1)

According to Forbes, “It’s unclear exactly how Medicaid programs will deal with ... the coming wave of Hepatitis C drugs also expected to get Food and Drug Administration approval from Abbvie (ABBV), Bristol-Myers (BMS) and Merck (MRK).” (2) The CBCD welcomes these new drugs because we believe they will increase competition between the pharmaceutical companies who manufacture the drugs, and thereby drive costs down.

What other treatments are currently available against the HCV virus?

Until recently, “the combination of a pegylated interferon (IFN)- $\alpha$  and ribavirin (was) the standard treatment for chronic HCV infections. This combination is effective in about 80% of the individuals infected with the HCV genotype 2 or 3, and in about 40% – 50% in those infected with genotype 1 or 4. Lately, two new drugs were approved, telaprevir and boceprevir, with better results. However, the combinations of pegylated interferon (IFN)- $\alpha$  and ribavirin and telaprevir or boceprevir are associated with additional side effects, increased costs, and more complex treatment strategies.” (3) There are also newly approved drugs including Sovaldi, Harvoni, and Virkira Pak.

“Unlike these costly drugs, Novirin and Gene-Eden-VIR are natural remedies designed to target the latent HCV.” - Greg Bennett, CBCD

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Cohn, M. "Hepatitis C drug can cure, if patients can get it" Published July 18, 2015  
baltimoresun.com

(2) Forbes.com - As Pricey Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles.  
Published October 10, 2014.  
<http://www.forbes.com/sites/brucejapsen/2014/10/10/as-hepatitis-pill-harvoni-joins-sovaldi-states-erect-medicaid-hurdles/>

(3) Gene-Eden-VIR is Antiviral: Results of a Post marketing clinical study. Published in September 2013. scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VE44nyKUf90

Greg Bennett  
CBCD  
585-250-9999  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.





